Chen Yongkang, Li Yuan, Wang Xiaohuan, Zou Peng
Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Front Microbiol. 2020 Jan 30;10:3079. doi: 10.3389/fmicb.2019.03079. eCollection 2019.
The association of Zika virus (ZIKV) infection and severe complications including neurological sequelae especially fetal microcephaly has aroused global attentions since its outbreak in 2015. Currently, there are no vaccines or therapeutic drugs clinically approved for treatments of ZIKV infection, however. And the drugs used for treating ZIKV in pregnant women require a higher safety profile. Here, we identified an anti-asthmatic drug, montelukast, which is of safety profile for pregnant women and exhibited antiviral efficacy against ZIKV infection and . And we showed that montelukast could disrupt the integrity of the virions to release the viral genomic RNA, hence irreversibly inhibiting viral infectivity. In consideration of the neuro-protective activity that montelukast possessed, which was previously reported, it is promising that montelukast could be used for patients with ZIKV infection, particularly for pregnant women.
自2015年寨卡病毒（ZIKV）疫情爆发以来，其感染与包括神经后遗症尤其是胎儿小头畸形在内的严重并发症之间的关联引起了全球关注。然而，目前尚无临床批准用于治疗ZIKV感染的疫苗或治疗药物。而且用于治疗孕妇ZIKV感染的药物需要更高的安全性。在此，我们鉴定出一种抗哮喘药物孟鲁司特，其对孕妇具有安全性，并且对ZIKV感染表现出抗病毒效力。并且我们表明孟鲁司特可破坏病毒粒子的完整性以释放病毒基因组RNA，从而不可逆地抑制病毒感染性。鉴于先前报道的孟鲁司特所具有的神经保护活性，孟鲁司特有望用于ZIKV感染患者，尤其是孕妇。
